Right Arm Lesion Found in 37-Year-Old Man

Combination therapy with nivolumab and relatlimab produces superior progression-free survival vs nivolumab monotherapy among those with advanced melanoma in the phase 3 RELATIVITY-047 trial.

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.

Targeting apoptosis in BRAF V600-mutated melanoma may be considered for future exploration in the post immunotherapy setting, according to an expert at Moffitt Cancer Center.

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.

Common treatment-emergent adverse effects among patients receiving PRT811 for uveal melanoma or advanced glioma include nausea and vomiting in a phase 1 study.

A real-world population of patients with relapsed/refractory B-cell acute lymphoblastic leukemia are reported to have had a high rate of complete remissions following treatment with brexucabtagene autoleucel.